Table 1.
Percentage of Enterobacterales and P. aeruginosa isolates from Latin America with MDR phenotypes stratified by year.
| % MDRa |
|||||||
|---|---|---|---|---|---|---|---|
| 2015‒2020 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | |
| Enterobacterales (n = 15,215) | 23.3% | 21.7% | 22.8% | 21.3% | 23.7% | 31.5% | 32.4% |
| P. aeruginosa (n = 4614) | 25.1% | 27.6% | 26.0% | 23.0% | 25.2% | 26.1% | 23.5% |
a
An MDR phenotype was defined as resistant to ≥ 3 sentinel agents, including: amikacin, aztreonam, cefepime, colistin, levofloxacin, meropenem, and piperacillin-tazobactam. The n for Enterobacterales/P. aeruginosa by year was: 2015, 2353/707; 2016, 2662/665; 2017, 2797/692; 2018, 2255/583; 2019, 2428/912; and 2020, 2720/1055.